Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Respiratory SystemDRG 181-respiratory-neoplasms-with-cc
    Ask Trek AI about this page

    Respiratory Neoplasms with CC: Inpatient Reimbursement Overview

    DRG 181 encompasses inpatient care for respiratory neoplasms when a complication or comorbidity is present, reflecting moderate clinical complexity in thoracic oncology. Accurate classification matters for inpatient reimbursement because it determines Medicare payment grouping, influences case-mix index calculations, and affects hospital revenue under the inpatient prospective payment system.

    Customize your policy alerts

    Sign up for drg 181 policy alerts

    Get alerted when payer policies referencing 181 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 181 Overview

    DRG 181 covers inpatient admissions for respiratory neoplasms with a Complication or Comorbidity, typically including primary lung cancers and other malignant tumors of the respiratory tract when an associated clinical complication or comorbidity is present. This Diagnosis-Related Group groups cases with moderate clinical complexity that influence resource use and length of stay. It matters for Medicare payment because classification into this DRG affects base payment rates, allocation of additional payments for outliers, and hospital case-mix indexing under the inpatient prospective payment system. Payers and hospital finance teams monitor this DRG due to its frequency and potential impact on reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Trials evaluating perioperative and inpatient systemic therapy sequencing for patients hospitalized with respiratory neoplasms and major comorbidities: these studies test timing and tolerability of chemotherapy, targeted agents, or immunotherapy given in the acute inpatient setting or immediately before/after thoracic surgery in patients with significant CC (complications/comorbidities such as COPD, heart failure, or renal impairment). The research addresses which sequencing or dose-adjustment strategies reduce inpatient complications, length of stay, and readmissions, information that matters to clinicians deciding on safe inpatient oncologic management and to payers concerned with resource use and complication-related costs.
    • Comparative effectiveness studies of inpatient management pathways for acute respiratory complications of thoracic malignancy (eg, malignant pleural effusion drainage strategies, inpatient radiation palliation versus medical symptom control): these trials compare procedural approaches, timing of interventions, or bundled pathways in patients admitted with symptom-producing respiratory tumors and associated comorbid conditions. Results inform which approaches produce faster symptom relief, fewer inpatient procedures or ICU transfers, and lower total cost of stay—critical for hospitals optimizing care for this high-acuity DRG and for payers evaluating value of different inpatient interventions.
    • Post-discharge outcomes and transitional-care interventions for patients with respiratory neoplasms complicated by comorbid conditions: pragmatic trials test enhanced discharge planning, early outpatient oncology follow-up, or home-based symptom monitoring for patients recently hospitalized with respiratory tumors and CC to reduce 30- and 90-day readmissions, treatment interruptions, and hospice transition timing. These studies focus on real-world populations with multimorbidity and are relevant to providers and payers because improved transitions can lower costly readmissions and align care with patient goals while preserving continuity of oncologic treatment.

    Related Codes

    163-MAJOR-CHEST-PROCEDURES-WITH-MCC

    Major Chest Procedures with MCC: Inpatient Reimbursement Overview

    164-MAJOR-CHEST-PROCEDURES-WITH-CC

    Major Chest Procedures with CC: Inpatient Reimbursement Overview

    165-MAJOR-CHEST-PROCEDURES-WITHOUT-CC-MCC

    Major Chest Procedures without CC/MCC: Inpatient Reimbursement Overview

    166-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITH-MCC

    Other Respiratory System O.R. Procedures with MCC: Inpatient Reimbursement Overview

    167-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITH-CC

    Other Respiratory System O.R. Procedures with CC: Inpatient Reimbursement Overview

    168-OTHER-RESPIRATORY-SYSTEM-O-R-PROCEDURES-WITHOUT-CC-MCC

    Other Respiratory System O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    173-ULTRASOUND-ACCELERATED-AND-OTHER-THROMBOLYSIS-WITH-PRINCIPAL-DIAGNOSIS-PULMONARY-EMBOLISM

    Ultrasound Accelerated and Other Thrombolysis with Principal Diagnosis Pulmonary Embolism: Inpatient Reimbursement Overview

    175-PULMONARY-EMBOLISM-WITH-MCC-OR-ACUTE-COR-PULMONALE

    Pulmonary Embolism with MCC or Acute Cor Pulmonale: Inpatient Reimbursement Overview

    176-PULMONARY-EMBOLISM-WITHOUT-MCC

    Pulmonary Embolism without MCC: Inpatient Reimbursement Overview

    177-RESPIRATORY-INFECTIONS-AND-INFLAMMATIONS-WITH-MCC

    Respiratory Infections and Inflammations with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 40

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.